The use of natriuretic peptide assay in dyspnea;Übersichtsarbeit: Bestimmung natriuretischer peptide bei atemnot

Deutsches Arzteblatt

Volumn 105, Issue 6, 2008, Pages 95-100

  Christ, Michael ^a   Mueller, Christian ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Acute dyspnea; Acute heart failure; Diagnosis; Natriuretic peptides; Prognosis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ACUTE HEART INFARCTION; ARTICLE; COST EFFECTIVENESS ANALYSIS; DIASTOLIC DYSFUNCTION; DYSPNEA; HEART FAILURE; HUMAN; SYSTOLIC DYSFUNCTION; VALVULAR HEART DISEASE;

EID: 39749136440     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2008.0095     Document Type: Article

References (25)

1. Christ M, Laule-Kilian K, Hochholzer W et al.: Gender-specific risk stratification with B-type natriuretic peptide levels in patients with acute dyspnea: insights from the B-type natriuretic peptide for acute shortness of breath evaluation study. J Am Coll Cardiol 2006; 48: 1808-12.
2. Wang CS, FitzGerald JM, Schulzer M, Mak E, Ayas NT: Does this dyspneic patient in the emergency department have congestive heart failure? JAMA 2005; 294: 1944-56.
3. de Lemos JA, McGuire DK, Drazner MH: B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316-22.
4. Silver MA, Maisel A, Yancy CW et al.: BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 2004; 10: 1-30.
5. McCullough PA, Nowak RM, McCord J et al.: B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002; 106: 416-22.
6. Maisel A: B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. Rev Cardiovasc Med 2002; 3 (Suppl. 4): S10-7.
7. Wang TJ, Larson MG, Levy D et al.: Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109: 594-600.
8. Mueller C, Scholer A, Laule-Kilian K et al.: Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350: 647-54.
9. Nieminen MS, Bohm M, Cowie MR et al.: Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 384-416.
10. Le Jemtel TH, Padeletti M, Jelic S: Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2007; 49: 171-80.
11. Maisel AS, Krishnaswamy P, Nowak RM et al.: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-7.
12. Mueller C, Laule-Kilian K, Schindler C et al.: Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med 2006; 166: 1081-7.
13. Doust JA, Pietrzak E, Dobson A, Glasziou P: How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005; 330: 625-33.
14. Berger R, Huelsman M, Strecker K et al.: B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 2392-7.
15. Christ M, Sharkova J, Bayrakcioglu S, Herzum I, Mueller C, Grimm W: B-type natriuretic peptide levels predict event-free survival in patients with implantable cardioverter defibrillators. Eur J Heart Fail 2007; 9: 272-9.
16. Horwich TB, Patel J, MacLellan WR, Fonarow GC: Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003; 108: 833-8.
17. Christ M, Laule K, Klima T et al.: Multimarker strategy for risk prediction in patients presenting with acute dyspnea to the emergency department. Int J Cardiol 2007; (in press).
18. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-30.
19. Jourdain P, Jondeau G, Funck F et al.: Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007; 49: 1733-9.
20. de Lemos JA, Morrow DA, Bentley JH et al.: The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014-21.
21. Weber M, Hausen M, Arnold R et al.: Prognostic value of N-terminal pro-B-type natriuretic peptide for conservatively and surgically treated patients with aortic valve stenosis. Heart 2006; 92: 1639-44.
22. Detaint D, Messika-Zeitoun D, Avierinos JF et al.: B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome. Circulation 2005; 111: 2391-7.
23. Mueller C, Breidthardt T, Laule-Kilian K, Christ M, Perruchoud AP: The integration of BNP and NT-proBNP into clinical medicine. Swiss Med Wkly 2007; 137: 4-12.
24. Christ M, Thuerlimann A, Laule-Kilian K et al.: Long-term prognostic value of B-type natriuretic peptide levels in cardiac and non-cardiac causes of acute dyspnea. Eur J Clin Invest 2007; 37: 834-41.
25. Januzzi JL, Camargo CA, Anwaruddin S et al.: The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005; 95: 948-54.